Novavax Inc
NVAX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$9.70
KIRA · Stoqly’s AI analyst, in plain words
- Novavax Inc had $1.1B of revenue in fiscal 2025, up 64.7% on the year before. Over five years, revenue changed +18.8% a year on average.
- Its operating margin was 40.3%, up 76.8 pts: of every 100 in sales, about 40 is left after running the business.
- Novavax Inc made $440M of net profit in fiscal 2025.
- Novavax Inc has $486M more cash than debt.
Market cap
$1.6B
P/E
—
Revenue
$1.1B
Net income
$440M
Free cash flow
—
Operating margin
40.3%
Novavax Inc in 30 seconds · fiscal 2025
Are sales growing?
+64.7%
Yes. Sales grew 64.7% last year.
Does it make a profit?
39.2%
Yes. It keeps 39.2% of every sale as profit.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Novavax Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- NOVAVAX INC
- CIK
- 0001000694
Novavax Inc · NVAX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.1B | $2.0B | $984M | $682M | $1.1B |
| Revenue growth | 141.0% | 72.9% | −50.4% | −30.7% | 64.7% |
| Gross margin | 100.0% | 54.5% | 65.1% | 70.3% | 93.5% |
| Operating margin | −147.1% | −32.5% | −57.6% | −36.5% | 40.3% |
| Net income | −$1.7B | −$658M | −$545M | −$187M | $440M |
| Net margin | −152.1% | −33.2% | −55.4% | −27.5% | 39.2% |
| Diluted EPS | −$23.44 | −$8.42 | −$5.41 | −$1.23 | $2.58 |
| Cash | |||||
| Cash from operations | $323M | −$416M | −$714M | −$87.3M | −$245M |
| Capital expenditure | $57.5M | — | — | — | — |
| Free cash flow | $265M | — | — | — | — |
| FCF margin | 23.2% | — | — | — | — |
| Share count change | 29.3% | 5.1% | 28.9% | 51.0% | 13.7% |
| Debt and strength | |||||
| Cash and short-term investments | $1.5B | $1.3B | $569M | $923M | $735M |
| Debt incl. finance leases | — | — | — | — | $249M |
| Shareholders' equity | −$352M | −$634M | −$717M | −$624M | −$128M |
| Net debt / EBITDA | — | — | — | — | −1.0x |
| Current ratio | 0.9x | 0.7x | 0.7x | 1.0x | 2.1x |
| Interest coverage | −79.8x | −32.4x | −39.3x | −12.4x | 20.1x |
| Returns and quality | |||||
| Return on equity | −1,265.7% | — | — | — | — |
| Piotroski F-score | 3 | 3 | 2 | 4 | 5 |
| Altman Z'' | −9.7 | −10.5 | −13.0 | −11.9 | −7.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Novavax Inc · NVAX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.70 a share, the company is worth $1.6B.
Source: SEC EDGAR XBRL filings (CIK 0001000694). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.